Back to news

Xtant Medical Reports Third Quarter 2026 Financial Results and Announces Board-led Strategic Review Process

PR Newswire•16/11/2026•07:00 ET
2

Key Highlights

  • ➤Q3 revenue $24.3 million, down from $33.3 million year-over-year
  • ➤Biologics revenue $19.3 million, up 13% year-over-year
  • ➤Board launches strategic review covering partnerships, financings, acquisitions and other alternatives
  • ➤Company withdraws previously issued full-year 2026 guidance
  • ➤Q3 net loss $3.6 million versus $1.3 million net income year-over-year

Expert Statements

Stavros Vizirgianakis, Chairman of the Board, Xtant Medical

“The Board is disappointed with Xtant's financial performance this quarter, which marks the second consecutive quarter in which our results have not met our guidance. That is unacceptable,”

Stavros Vizirgianakis, Chairman of the Board, Xtant Medical

“Certain directors, including me, have invested their own capital in Xtant, and the Board includes a representative of our largest stockholder. The Board feels this shortfall as owners and stewards of the Company, not just as directors, and the Board's interests are directly aligned with stockholders.”

Stavros Vizirgianakis, Chairman of the Board, Xtant Medical

“The Board's priorities are clear: improve execution, improve financial performance, and maximize stockholder value through the strategic review process. Already we are encouraged by how our core biologics business is gaining momentum both quarter-over-quarter and year-over-year.”

Xtant Medical Reports Third Quarter 2026 Financial Results and Announces Board-led Strategic Review Process PR Newswire

Board reiterates commitment to improving performance and maximizing stockholder value; has been actively involved in a comprehensive review of a broad range of strategic, operational, and financial alternatives.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in